PAG
AUPH icon

Private Advisor Group’s Aurinia Pharmaceuticals AUPH Stock Holding History

Private Advisor Group’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-850
Closed -$14K – 1705
2020
Q2 		$14K Buy
+850
New +$13.6K ﹤0.01% 2746
2017
Q3 		– Sell
-10,000
Closed -$62K – 1466
2017
Q2 		$62K Buy
+10,000
New +$67.4K ﹤0.01% 1347

Other funds holding AUPH

HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Private Advisor Group's AUPH Position: Q3 2020 in Review

Private Advisor Group sold out of Aurinia Pharmaceuticals (AUPH) in Q3 2020, closing a stake of 850 shares — an estimated $14K sold.

Private Advisor Group first reported a position in AUPH in Q2 2017 and held it in 2 quarters. The position peaked at $62K in Q2 2017. 145 funds tracked by Wall St. Rank hold AUPH as of Q3 2020.

  • Private Advisor Group reported no remaining Aurinia Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Private Advisor Group sold 850 Aurinia Pharmaceuticals shares in Q3 2020, an estimated $14K.
  • Private Advisor Group first reported a position in Aurinia Pharmaceuticals in Q2 2017 and held it in 2 quarters.
  • Private Advisor Group's Aurinia Pharmaceuticals position peaked at $62K in Q2 2017.
  • 145 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2020.

Based on Private Advisor Group's 13F filing for Q3 2020, filed 2 Nov 2020.